Article

Pearson Syndrome in the Neonatal Period

AP-HP, Hôpital Armand Trousseau, Department of Pediatric Hematology Oncology and Université Pierre et Marie Curie, Paris, France.
Journal of Pediatric Hematology/Oncology (Impact Factor: 0.9). 10/2009; 31(12):947-51. DOI: 10.1097/MPH.0b013e3181bbc4ef
Source: PubMed

ABSTRACT

Pearson syndrome is a multiorgan mitochondrial cytopathy that results from defective oxidative phosphorylation owing to mitochondrial DNA deletions. Prognosis is severe and death occurs in infancy or early childhood. This article describes 2 cases with a severe neonatal onset of the disease. A review of the literature reveals the atypical presentation of the disease in the neonatal period, which is often overlooked and underdiagnosed.

1 Follower
 · 
26 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To study the prevalence and prognostic importance of mutations in NADH dehydrogenase subunit 4 (ND4), a mitochondrial encoded transmembrane component of the electron transport chain respiratory Complex I, 452 AML patients were examined for ND4 mutations by direct sequencing. The prognostic impact of ND4 mutations was evaluated in the context of other clinical prognostic markers and genetic risk factors. In all, 29 of 452 patients (6.4%) had either somatic (n=12) or germline (n=17) ND4 mutations predicted to affect translation. Somatic mutations were more likely to be heteroplasmic (P<0.001), to occur in predicted transmembrane domains (P<0.001) and were predicted to have damaging effects upon translation (P<0.001). Patients with somatically acquired ND4 mutations had significantly longer relapse-free survival (P=0.017) and overall survival (OS) (P=0.021) than ND4(wildtype) patients. Multivariate analysis also demonstrated a tendency for increased survival in patients with somatic ND4 mutations (RFS: hazard ratio (HR) 0.25, confidence interval (CI) 0.06-1.01, P=0.052; OS: HR 0.29, CI 0.74-1.20, P=0.089). Somatic ND4(mutated) patients had a higher prevalence of concomitant DNMT3A mutations (P=0.023) and a higher percentage of the NPM1/FLT3-ITD low-risk genotype (P=0.021). Germline affected cases showed higher BAALC (P=0.036) and MLL5 (P=0.051) expression levels. Further studies are warranted to validate the favorable prognostic influence of acquired ND4 mutations in AML.
    Full-text · Article · Aug 2011 · Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Among the etiologies of anemia in the infancy, the mitochondrial cytopathies are infrequent. Pearson syndrome is diagnosed principally during the initial stages of life and it is characterized by refractory sideroblastic anemia with vacuolization of marrow progenitor cells, exocrine pancreatic dysfunction and variable neurologic, hepatic, renal and endocrine failures. We report the case of a 14 month-old girl evaluated by a multicentric study, with clinic and molecular diagnosis of Pearson syndrome, with the 4,977-base pair common deletion of mitochondrial DNA. This entity has been associated to diverse phenotypes within the broad clinical spectrum of mitochondrial disease.
    Full-text · Article · Sep 2011 · Investigación clínica
  • [Show abstract] [Hide abstract]
    ABSTRACT: The term anemia refers to a pathological reduction in the hematocrit, blood hemoglobin concentration, and circulating erythrocyte count [1, 2]. These three laboratory measures are somewhat similar to one another, in that each quantifies the same biological variable involving the capacity of blood to deliver oxygen to tissues. However, none of the three measurements actually assesses whether oxygen demands of tissues are being adequately met. In fact, limitations in delivery of oxygen to a neonate’s tissues are frequently not the result of anemia at all, but instead are due to abnormalities in oxygen intake from pulmonary pathology. This chapter reviews the various pathologies that give rise to anemia during the neonatal period, and provides practical approaches for dealing with these clinical issues.
    No preview · Chapter · Jan 2012
Show more